The impact of regulations, tradition, and experimental design on clinical cancer trials: Report and recommendations resulting from Washington Cancer Trials Conference

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 4, 1996, Pages 325-329

  Lasagna, Louis ^a   Frei III, Emil ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER RESEARCH; CONFERENCE PAPER; DOSE RESPONSE; ETHICS; HEALTH CARE COST;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DIFFUSION OF INNOVATION; DISTRICT OF COLUMBIA; ETHICS COMMITTEES; HUMANS; NEOPLASMS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0029937239     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199608000-00001     Document Type: Conference Paper

References (2)

1. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M. J Clin Oncol Preceptions of cancer patients and their physicians involved in Phase I trials. 1995; 13:1062-72.
2. Schipper H, Golt CR, Wang TL. Shifting the cancer paradigm: Must we kill to cure? J Clin Oncol 1995;13:801-7.